Drug intelligence / Profile preview

SENTINEL

Development stage: Unknown
Lead developer: Novartis
Modality: Small Molecules

Overview

SENTINEL is a brand of combination parasiticide for dogs, designed to protect against fleas, heartworm, and other internal parasites. It was initially part of Novartis Animal Health, then divested to Virbac, and subsequently, Merck acquired the U.S. rights to the brand in July 2020 to expand its companion animal business.

Brand names: SENTINEL
Other names: lufenuron + milbemycin oxime

Targets

Chitin Synthase (Insect)GluCl (Glutamate-gated chloride channel)

Beyond the preview

Go deeper on SENTINEL.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SENTINEL.

Explore the full profile